Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2005
We are writing in response to Bigby’s article1 in this issue of the ARCHIVES. Additional data for our original study2 separating facial and intertriginous psoriasis are provided herein in the Table. If you compare the active drug group with the placebo group for number of patients with only facial psoriasis whose total score was 0 for disease signs and symptoms for the target lesion at the end of the study, it is clear that tacrolimus treatment showed a statistically significant benefit: the lesions on 19 (42%) of 45 patients receiving active treatment cleared compared with those of only 1 (6%) of 17 vehicle-treated patients (P = .006). There was also a statistically significant benefit for intertriginous areas only: the lesions on 32 (48%) of 67 tacrolimus-treated patients cleared compared with those on only 5 (14%) of 37 vehicle-treated patients (P<.001).
Lebwohl M, Freeman A, Chapman MS, Feldman S, Hartle J, Henning A. Proven Efficacy of Tacrolimus for Facial and Intertriginous Psoriasis. Arch Dermatol. 2005;141(9):1154. doi:10.1001/archderm.141.9.1154